Alan Landay to HIV-1
This is a "connection" page, showing publications Alan Landay has written about HIV-1.
Connection Strength
12.152
-
The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women. AIDS Res Hum Retroviruses. 2016 Feb; 32(2):134-43.
Score: 0.425
-
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses. 2015 Feb; 31(2):208-16.
Score: 0.398
-
The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol. 2009 Mar; 130(3):298-303.
Score: 0.263
-
The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr. 2008 Aug 15; 48(5):577-80.
Score: 0.258
-
Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS. 2008 Mar 30; 22(6):671-83.
Score: 0.252
-
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol. 2007 Nov-Dec; 250(1-2):75-84.
Score: 0.251
-
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol. 2007 Sep; 14(9):1102-7.
Score: 0.240
-
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
Score: 0.235
-
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 01; 44(5):749-54.
Score: 0.232
-
Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy. Expert Rev Anti Infect Ther. 2006 Oct; 4(5):767-80.
Score: 0.227
-
Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol. 2005 Aug 01; 45(2):129-36.
Score: 0.205
-
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.
Score: 0.192
-
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2003 Nov 15; 188(10):1444-54.
Score: 0.186
-
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003 Mar 07; 17(4):455-80.
Score: 0.177
-
Editorial: Advances in T Cell Therapeutic Vaccines for HIV. Front Immunol. 2022; 13:905836.
Score: 0.167
-
Trophoblasts are productively infected by CD4-independent isolate of HIV type 1. AIDS Res Hum Retroviruses. 2002 Jan 01; 18(1):13-7.
Score: 0.163
-
Overt IL-32 isoform expression at intestinal level during HIV-1 infection is negatively regulated by IL-17A. AIDS. 2021 10 01; 35(12):1881-1894.
Score: 0.161
-
Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 2001 Sep 07; 15(13):1635-41.
Score: 0.160
-
Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.
Score: 0.151
-
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
Score: 0.146
-
Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol. 2000 May; 7(3):352-9.
Score: 0.145
-
Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.
Score: 0.145
-
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. J Acquir Immune Defic Syndr. 2019 12 15; 82(5):503-513.
Score: 0.142
-
Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin Immunol. 1999 Jun; 91(3):254-62.
Score: 0.137
-
Cytokine modulation of HIV-1 chemokine receptor expression. Nat Med. 1999 Jun; 5(6):592-3.
Score: 0.137
-
Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Lancet. 1999 Jan 16; 353(9148):211-2.
Score: 0.133
-
Induction of HIF-1a by HIV-1 Infection in CD4+ T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation. mBio. 2018 09 11; 9(5).
Score: 0.130
-
Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production. J Clin Immunol. 1998 Mar; 18(2):124-31.
Score: 0.125
-
Lymphocyte phenotyping in infants: maturation of lymphocyte subpopulations and the effects of HIV infection. Clin Immunol Immunopathol. 1997 Dec; 85(3):273-81.
Score: 0.123
-
Inhibition of cytokine-driven human immunodeficiency virus type 1 replication by protease inhibitor. J Infect Dis. 1997 Nov; 176(5):1175-9.
Score: 0.122
-
A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women. AIDS. 1997 Sep; 11(11):1319-26.
Score: 0.121
-
Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):e132-e141.
Score: 0.121
-
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol. 2018 03; 11(2):449-461.
Score: 0.120
-
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2016 Mar 27; 30(6):869-78.
Score: 0.110
-
Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):155-62.
Score: 0.108
-
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71.
Score: 0.108
-
Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):172-80.
Score: 0.108
-
IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol. 1996 Jan 15; 156(2):841-51.
Score: 0.108
-
Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol. 2016 Jan; 9(1):24-37.
Score: 0.103
-
CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. PLoS One. 2015; 10(3):e0115019.
Score: 0.102
-
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406.
Score: 0.098
-
Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014; 9(3):e86461.
Score: 0.095
-
An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014 Jul; 7(4):983-94.
Score: 0.094
-
A rapid manual method for CD4+ T-cell quantitation for use in developing countries. AIDS. 1993 Dec; 7(12):1565-8.
Score: 0.093
-
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
Score: 0.089
-
Detection of HIV-1 provirus in bronchoalveolar lavage cells by polymerase chain reaction. J Acquir Immune Defic Syndr (1988). 1993 Feb; 6(2):171-5.
Score: 0.088
-
Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals. AIDS. 1992 Sep; 6(9):1047.
Score: 0.086
-
MDSC: a new player in HIV immunopathogenesis. AIDS. 2012 Jul 31; 26(12):1567-9.
Score: 0.085
-
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis. 2012 Sep 15; 206(6):969-73.
Score: 0.085
-
Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis. 2012 Sep 01; 206(5):780-9.
Score: 0.084
-
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
Score: 0.083
-
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012; 7(1):e30306.
Score: 0.082
-
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS. 2011 Sep 24; 25(15):1823-32.
Score: 0.080
-
Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS. 2011 Jun 01; 25(9):1207-17.
Score: 0.078
-
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol. 2010 Sep; 17(9):1452-9.
Score: 0.074
-
Isolation of HIV-1 from monocytes of individuals negative by conventional culture. J Infect Dis. 1990 Apr; 161(4):706-10.
Score: 0.072
-
Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol. 2010 Apr; 135(1):12-25.
Score: 0.071
-
Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010 Feb; 54(2):871-81.
Score: 0.071
-
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009 Jun 18; 113(25):6304-14.
Score: 0.068
-
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13; 23(5):605-10.
Score: 0.067
-
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
Score: 0.067
-
Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells. Virology. 2009 Mar 01; 385(1):22-7.
Score: 0.066
-
Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):348-57.
Score: 0.066
-
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol. 2008 Oct; 129(1):132-44.
Score: 0.064
-
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19; 22(10):1131-5.
Score: 0.064
-
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008 May 15; 197(10):1402-7.
Score: 0.063
-
Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J Infect Dis. 2008 Jan 15; 197(2):319-27.
Score: 0.062
-
Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology. 2007 Dec 05; 369(1):55-68.
Score: 0.060
-
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS. 2007 Jan 30; 21(3):293-305.
Score: 0.058
-
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis. 2007 Mar 01; 195(5):734-8.
Score: 0.058
-
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
Score: 0.058
-
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71.
Score: 0.057
-
Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol. 2006 Oct; 80(20):10162-72.
Score: 0.057
-
Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. FEMS Immunol Med Microbiol. 2006 Nov; 48(2):267-73.
Score: 0.057
-
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006 Jul 01; 194(1):29-37.
Score: 0.055
-
Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol. 2006 Aug; 120(2):138-46.
Score: 0.055
-
HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol. 2006 Mar; 125(3):386-91.
Score: 0.054
-
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005 Nov 01; 192(9):1577-87.
Score: 0.053
-
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
Score: 0.052
-
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 2004 Dec 01; 190(11):1970-8.
Score: 0.050
-
HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis. 2004 Aug 01; 190(3):619-23.
Score: 0.049
-
Mother-to-child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr. 2004 Jun 01; 36(2):659-70.
Score: 0.048
-
Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13.
Score: 0.047
-
Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood. 2004 Jun 15; 103(12):4581-7.
Score: 0.047
-
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004 Jan 16; 303(5656):316.
Score: 0.047
-
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
Score: 0.047
-
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14.
Score: 0.047
-
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8.
Score: 0.046
-
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12972-7.
Score: 0.046
-
Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.
Score: 0.046
-
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003 Jul 15; 188(2):209-18.
Score: 0.045
-
CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood. 2003 Sep 15; 102(6):2156-64.
Score: 0.045
-
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003 Feb 01; 187(3):375-84.
Score: 0.044
-
CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology. 2003 Jan; 108(1):3-9.
Score: 0.044
-
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol. 2002 Sep; 161(3):867-73.
Score: 0.043
-
HIV and Aging in the Era of ART and COVID-19: Symposium Overview. J Acquir Immune Defic Syndr. 2022 02 01; 89(Suppl 1):S3-S9.
Score: 0.041
-
Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis. 2002 Feb 15; 185(4):439-47.
Score: 0.041
-
Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001 Nov 10; 358(9293):1593-601.
Score: 0.040
-
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
Score: 0.040
-
HIV in the female genital tract: viral shedding and mucosal immunity. Clin Obstet Gynecol. 2001 Jun; 44(2):144-53.
Score: 0.039
-
Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest. 2001 Feb; 107(3):287-94.
Score: 0.038
-
Vaccines and immunology. Recent advances in HIV/AIDS vaccine development. AIDS. 2001; 15 Suppl 5:S101-3.
Score: 0.038
-
Up-regulation of CCR5 expression in the placenta is associated with human immunodeficiency virus-1 vertical transmission. Am J Pathol. 2000 Dec; 157(6):1811-8.
Score: 0.038
-
Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000 Dec 01; 25(4):289-95.
Score: 0.038
-
Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle. Women's Health Study (WHS) 001 and WHS 001a Study Team. J Womens Health Gend Based Med. 2000 Oct; 9(8):857-63.
Score: 0.037
-
Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000 Sep 29; 14(14):2101-7.
Score: 0.037
-
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb; 181(2):491-7.
Score: 0.036
-
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000 Jan 07; 14(1):11-21.
Score: 0.036
-
Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
Score: 0.036
-
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000 Jan; 181(1):141-7.
Score: 0.036
-
Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57.
Score: 0.036
-
Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol. 1999 Aug 01; 163(3):1666-73.
Score: 0.035
-
Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999 Jul 30; 13(11):1295-303.
Score: 0.035
-
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. AIDS. 1999 Jul 09; 13(10):1177-85.
Score: 0.034
-
Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J Acquir Immune Defic Syndr. 1999 Jul 01; 21(3):194-202.
Score: 0.034
-
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. Infect Control Hosp Epidemiol. 1999 Jun; 20(6):428-30.
Score: 0.034
-
Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999 May 28; 13(8):919-25.
Score: 0.034
-
Levels of proinflammatory cytokines in plasma after pneumoccoccal immunization in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 1999 May; 6(3):427-8.
Score: 0.034
-
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.
Score: 0.034
-
Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA. 1999 Mar 24-31; 281(12):1085-6.
Score: 0.034
-
Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 01; 19(4):408-12.
Score: 0.033
-
Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol. 1998 Nov; 72(11):9054-60.
Score: 0.033
-
A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis. 1998 Nov; 178(5):1343-51.
Score: 0.033
-
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
Score: 0.032
-
Rationale for immune-based therapies for HIV-1 infection. J Lab Clin Med. 1998 Mar; 131(3):197-206.
Score: 0.031
-
Brief Report: Inflammatory Colonic Innate Lymphoid Cells Are Increased During Untreated HIV-1 Infection and Associated With Markers of Gut Dysbiosis and Mucosal Immune Activation. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):431-437.
Score: 0.031
-
Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 01; 16(3):161-8.
Score: 0.031
-
The Th17 Lineage: From Barrier Surfaces Homeostasis to Autoimmunity, Cancer, and HIV-1 Pathogenesis. Viruses. 2017 10 19; 9(10).
Score: 0.031
-
Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997 Jul; 11(8):1013-21.
Score: 0.030
-
CD56bright NK IL-7Ra expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. J Leukoc Biol. 2017 07; 102(1):171-184.
Score: 0.029
-
In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 1997 Jan; 4(1):43-8.
Score: 0.029
-
Contribution of prostaglandin E2 to the interleukin-12 defect in HIV-infected patients. AIDS. 1996 Aug; 10(9):1043-5.
Score: 0.028
-
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 1995 Aug; 96(2):867-76.
Score: 0.026
-
Effect of zidovudine therapy on CD8+ T cell anti-HIV activity. Clin Immunol Immunopathol. 1994 Oct; 73(1):80-7.
Score: 0.025
-
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014; 9(2):e85869.
Score: 0.024
-
HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994 Jan 05; 271(1):42-6.
Score: 0.023
-
Characterization of CD4? T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):232-40.
Score: 0.023
-
Postmortem recovery of human immunodeficiency virus type 1 from plasma and mononuclear cells. Implications for occupational exposure. Arch Pathol Lab Med. 1992 Nov; 116(11):1124-7.
Score: 0.022
-
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
Score: 0.021
-
The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res. 2012 Apr; 10(3):202-10.
Score: 0.021
-
Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses. 1991 Jul; 7(7):579-85.
Score: 0.020
-
Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS. 1991 Mar; 5(3):269-74.
Score: 0.019
-
HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011 Jan 14; 25(2):159-64.
Score: 0.019
-
Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol. 1990 Dec; 64(12):5869-73.
Score: 0.019
-
Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection. J Infect Dis. 1990 Nov; 162(5):1018-24.
Score: 0.019
-
Human herpesvirus 6 inhibits human immunodeficiency virus type 1 replication in cell culture. J Clin Microbiol. 1990 Oct; 28(10):2362-4.
Score: 0.019
-
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65.
Score: 0.018
-
Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr. 2007 May 01; 45(1):9-19.
Score: 0.015
-
VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol. 2006 May 25; 7:11.
Score: 0.014
-
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
Score: 0.011
-
Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003 Jun 15; 187(12):1924-33.
Score: 0.011
-
Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr. 2002 Apr 15; 29(5):544-5.
Score: 0.010
-
Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000 Dec 01; 14(17):2635-42.
Score: 0.009
-
T cell responses to recall antigens, alloantigen, and mitogen of HIV-infected patients receiving long-term combined antiretroviral therapy. AIDS Res Hum Retroviruses. 2000 Nov 20; 16(17):1887-93.
Score: 0.009
-
Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA. 1998 Jul 01; 280(1):72-7.
Score: 0.008
-
Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis. 1997 Mar; 175(3):567-75.
Score: 0.007
-
HTLV-I activates complement leading to increased binding to complement receptor-positive cells. AIDS Res Hum Retroviruses. 1995 Sep; 11(9):1115-22.
Score: 0.007